Clinical Trials

SignalChem Lifesciences Corporation

SLC-391-102 (SKYLITE Study) A Single-Arm, Open-Label, Phase 1b/2 Study of SLC-391, an AXL Inhibitor, in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT05860296 > Key Eligibility: Inclusions: Minimum 2 line of therapy in advanced or metastatic setting, max of 4 lines of previous therapies; Exclusions: Prior therapy with AXL inhibitor (ex: bemcentinib), autoimmune disease, history of pneumonitis

Shenzhen Ionova Life Sciences Co., Ltd.

INV-1120-101 A Phase 1a/1b Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors NCT04443088 > Key Eligibility: Inclusion: Must be able to swallow and retain orally administered medication; Exclusions: Known serious allergy to investigational drug or excipients (microcrystalline cellulose); history (within 4 weeks of starting treatment) or evidence of active infections (Grade ≥2), any disorder or surgical procedure that could impact the absorption of study drug from the gastrointestinal tract, LVEF < 50% by ECHO or MUGA, history of use of H2 blockers (<24 hours before the first dose of study treatment and during the study) and proton pump inhibitors (<5 days before the first dose of study treatment and during the study), recent (within past 12 months) history, or are currently being treated for gastroesophageal ulcer

Lyvgen Biopharma Holdings, Limited

LVGN7409-101 An Open Label, First in Human (FIH), Phase 1a/1b Trial of LVGN7409 (CD40 agonist antibody) as a Single Agent, in Combination with LVGN3616 (anti-PD-1 antibody), and in Combination with LVGN3616 and LVGN6051 (CD137 agonist antibody) in Patients with Locally Advanced, Relapsed, Refractory, or Metastatic Malignancy NCT04130542 > Key Eligibility: Enrolling solid tumors and lymphoma. Must have refractory, intolerant to standard of care, or no standard of care exists; may have measurable or evaluable disease. Prior therapy with anti-CD40 therapy. Exclusions: Grade 3 drug toxicity with prior immunotherapies; clinically significant cardiac condition within 6 months; uncontrolled pleural effusion, pericardial effusion, or recurrent ascites drainage; no history of stroke within 6 months

Shanghai Huaota Biopharmaceutical Co., Ltd.

HB0036-01 A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors NCT05417321> Key Eligibility: Exclusion: Patient on antibiotics <1 week in the last 28 days, alcohol abuse and cannabis abuse, concurrent malignancy, active or history of irAEs (like pneumonitis) or autoimmune disease, uncontrolled diabetes and hypertension

Veloxis Pharmaceuticals, Inc.

ART-123.PN101 A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-FU /oxaliplatin and bevacizumab in mCRC NCT05251727> Key Eligibility: Inclusion: Patients with mCRC starting first line FOLFOX + Bevacizumab; Exclusion: History of bleeding or thromboembolic events due to risk of bleeding

Ranok Therapeutics Co. Ltd.

RNK05047-01 A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Chaperone-mediated Protein Degrader RNK05047 in Subjects with Advanced Solid Tumors (CHAMP-1) NCT05487170> Key Eligibility: Phase 1: Any solid tumor and DLBCL. Inclusion: Refractory or intolerant to all available standard of care therapy; BMI > 18; creatinine clearance > 60 mL/min, INR < 1.5; PTT < ULN; Exclusion: Peripheral neuropathy > Grade 2.

BioAtla, Inc.

BA3071-001 A phase 1/2 study of ba3071 in combination with nivolumab in patients with advanced solid tumors. NCT05180799 > Key Eligibility: Inclusion: Melanoma, mRCC, NSCLC, mUC, Gastric, SCLC, aHCC, Cervical; Exclusions: History of paracentesis; history of hepatic encephalopathy; prior treatment with CLTA-4 inhibitor; supplemental oxygen use

Lyvgen Biopharma Holdings, Limited

LVGN6051-101 An Open Label, First in Human (FIH), Phase 1 Trial of LVGN6051 as Single Agent and in Combination with Keytruda (pembrolizumab) in Advanced or Metastatic Malignancy NCT04130542 > Key Eligibility: Inclusions: Trial is currently enrolling patients in Phase 1b; patients in the Phase 1b portion of the trial must have a histologically or cytologically confirmed melanoma or NSCLC

LaNova Medicines, Ltd.

LM302-01-101 A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in patients with CLDN18.2 Positive Advanced Solid Tumors. NCT05001516 > Key Eligibility: Inclusion: Advanced solid tumors (gastric, GEJ, pancreatic, BTC, and mucinous ovarian); Exclusions: grade 2 peripheral neuropathy; uncontrolled tumor-related pain. Phase 1b expansion requires CLDN18.2 positive.